Inogen, Inc.

$6.41 ▲ 1.58%
2026-06-06 08:41:01

Explore Inogen, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$170.84 M
Current Price
$6.41
52W High / Low
$9.13 / $5.34
Stock P/E
Book Value
$7.06
Dividend Yield
ROCE
-12.85%
ROE
-12.9%
Face Value
EPS
$-0.92
Exp Qtr EPS
Sector
Healthcare

INGN — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Balance sheet leverage appears manageable.
  • Short-term liquidity looks comfortable.
  • Valuation is not stretched on P/E basis.

Cons

  • Return on equity is on the weaker side.
  • Capital efficiency is modest.
  • Operating margin is thin.
  • Net margin is relatively low.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Abbott Laboratories $91.07 25.38 $159.31 B 2.78% 11.47% 12.2% $139.06 / $81.97 $30.02
2. Stryker Corporation $305.66 35.21 $117.49 B 1.17% 12.63% 15.1% $404.87 / $281 $58.61
3. Medtronic plc $81.67 21.98 $105.57 B 0.03% 8.3% 9.54% $106.33 / $73.31 $37.46
4. Boston Scientific Corporation $48.55 20.71 $73.84 B 0% 10.39% 14.87% $109.5 / $47.16 $16.34
5. Edwards Lifesciences Corporation $85.96 45.25 $49.6 B 13.77% 10.59% $89.48 / $72.3 $17.8
6. GE HealthCare Technologies Inc. $64.67 15.4 $29.42 B 0.22% 9.93% 18.75% $89.77 / $58.75 $22.77
7. DexCom, Inc. $72.86 31.06 $28.9 B 21.72% 33.83% $89.98 / $54.11 $7.14

Quarterly Results

Figures shown in M / B

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales81.72 M92.39 M92.28 M82.28 M80.08 M
Operating Profit-9.31 M-7.12 M-6.13 M-7.66 M-11.39 M
Net Profit-7.13 M-5.29 M-4.15 M-6.17 M-9.76 M
EPS in Rs-0.26-0.19-0.15-0.23-0.36

Profit & Loss

Figures shown in M / B

2025202420232022
Sales348.67 M335.7 M315.66 M377.24 M
Operating Profit-30.21 M-42.52 M-76.49 M-33.08 M
Net Profit-22.75 M-35.89 M-102.45 M-83.77 M
EPS in Rs-0.84-1.32-3.76-3.08

Balance Sheet

Figures shown in M / B

2025202420232022
Total Assets298.62 M296.19 M326.19 M405.04 M
Total Liabilities106.39 M122.33 M121.38 M107.64 M
Equity192.23 M173.86 M204.81 M297.41 M
Current Assets198.3 M185.45 M207.07 M304.64 M
Current Liabilities63.53 M76.69 M72.5 M65.35 M

Cash Flow

Last available yearly cash flow history

2025202420232022
Operating CF-11.22 M5.91 M-3.23 M-37.53 M
Investing CF-26.21 M-13.97 M-59.31 M-10.88 M
Financing CF24.18 M0.27 M0.96 M0.38 M
Free CF-21.6 M-11.18 M-30.25 M-58.75 M
Capex-10.38 M-17.09 M-27.01 M-21.22 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

2024202320222021
Revenue Growth %6.35%-16.32%
Earnings Growth %64.97%-22.3%
Profit Margin %-10.69%-32.46%-22.21%
Operating Margin %-12.66%-24.23%-8.77%
Gross Margin %46.09%40.14%40.7%
EBITDA Margin %-6.41%-18.48%-2.54%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

No dividend history available.

Stock Splits

No stock split history available.

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
Columbia Funds Series Trust I-Columbia Small Cap Value Discovery Fund Mutual Fund 0.58 M $3.63 M 0.02% 2026-01-31
iShares Trust-iShares Russell 2000 ETF Mutual Fund 0.56 M $3.49 M 0.02% 2026-01-31
Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund Mutual Fund 0.37 M $2.31 M 0.01% 2026-01-31
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund Mutual Fund 0.23 M $1.44 M 0.01% 2026-01-31
iShares Trust-iShares Russell 2000 Value ETF Mutual Fund 0.2 M $1.22 M 0.01% 2026-01-31
Blackrock Inc. Institutional 1.72 M $10.66 M 0.06% 2025-12-31
Vanguard Group Inc Institutional 1.42 M $8.83 M 0.05% 2025-12-31
Armistice Capital, LLC Institutional 1.26 M $7.85 M 0.05% 2025-12-31
Acadian Asset Management. LLC Institutional 1.08 M $6.73 M 0.04% 2025-12-31
Ameriprise Financial, Inc. Institutional 0.86 M $5.34 M 0.03% 2025-12-31
DAFNA Capital Management, LLC Institutional 0.83 M $5.14 M 0.03% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund Mutual Fund 0.74 M $4.6 M 0.03% 2025-12-31
Dimensional Fund Advisors LP Institutional 0.71 M $4.42 M 0.03% 2025-12-31
Geode Capital Management, LLC Institutional 0.6 M $3.72 M 0.02% 2025-12-31
Goldman Sachs Group Inc Institutional 0.59 M $3.66 M 0.02% 2025-12-31

Frequently Asked Questions — Inogen, Inc.

Will Inogen, Inc. stock hit $8 in 2026?

Inogen, Inc. (INGN) is currently trading at $6.41, with a 52-week range of $5.34 to $9.13. Reaching the $8 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $12.67 for Inogen, Inc., with a Strong_buy rating, and the most bullish analysts see the stock reaching as high as $14.0. Whether Inogen, Inc. can reach $8 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, INGN has delivered a -36.7% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the INGN Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is Inogen, Inc. stock worth buying at $6.41?

Whether Inogen, Inc. (INGN) is worth buying at $6.41 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.

Profitability & efficiency: Inogen, Inc. has a Return on Capital Employed (ROCE) of -12.8%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -12.9%.

Financial health: The Debt-to-Equity ratio of 9.09 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for INGN is currently Strong_buy, with a mean price target of $12.67 based on 3 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for Inogen, Inc. (INGN) in 2026?

As of 2026, Wall Street analysts have set a consensus (mean) price target of $12.67 for Inogen, Inc. (INGN), aggregated from 3 analyst ratings. The overall analyst recommendation is Strong_buy.

The price target range spans from $12.0 on the bearish end to $14.0 on the most optimistic projection, with a median target of $12.0. This wide range reflects differing views on Inogen, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the INGN analysis page on StockSifting.

What will Inogen, Inc. stock be worth in 2029?

Projecting Inogen, Inc. (INGN)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on INGN's historical 5-year Compound Annual Growth Rate (CAGR) of -36.7%, if that rate of growth were to continue, the stock could reach approximately $2 by 2029 — up from its current price of $6.41. This projection assumes the historical CAGR holds, which depends on Inogen, Inc. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the INGN Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.